<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html lang="en" xml:lang="en" xmlns="http://www.w3.org/1999/xhtml">
<head>
<meta content="text/html; charset=utf-8" http-equiv="Content-Type"/>
<title>Ministry of Health &amp; Welfare : ABOUT MOHW &gt; Press Release View Content</title>
<link href="../../css/eng/mwf_eng.css" rel="stylesheet" type="text/css"/>
<script src="../../js/jquery-1.11.0.min.js" type="text/javascript"></script>
<script src="../../js/common.js" type="text/javascript"></script>
<script src="../../js/mw_eng.js" type="text/javascript"></script>
<script type="text/javascript">

//<![CDATA[



	// ¸®½ºÆ®·Î ÀÌµ¿

	function jsList()

	{

		var form = document.fmList;

		form.action = "ssg0111ls.jsp";

		form.submit();

	}



	//³»¿ë º¸±â

	function goView(seq)

	{

		var form = document.fmView;

		form.CONT_SEQ.value = seq;

		form.action = "ssg0111vw.jsp";

		form.submit();

	}



	//ÇÏ´Ü ¸®½ºÆ® ÆäÀÌÁö ÀÌµ¿

	function goPage( page)

	{

		var form = document.fmList;

		form.page.value = page;

		form.submit();

	}



	//ÆÄÀÏ ´Ù¿î·Îµå.

	function fileDownLoad(fileSeq)

	{

		if( confirm( "Do you wish to download now?") == true ) {

			var form = document.fmView;

			form.FILE_SEQ.value = fileSeq;

			form.action = "/front_new/modules/download.jsp";

			form.submit();

		}

	}

//]]>

</script>
</head>
<body>
<!-- ¹Ù·Î°¡±â ¸µÅ© -->
<p id="skip-navi">
<a href="#contents">go to the contents</a>
<a href="#snb">go to the menu</a>
</p>
<!-- //¹Ù·Î°¡±â ¸µÅ© -->
<!-- header -->
<div id="wrap">
<!-- head -->
<div class="sbHead" id="head">
<!-- header -->
<div id="header">
<!-- ·Î°í -->
<h1 class="logo"><a href="../261f58801c1da21d0b6f7021b30b648b"><img alt="ministry of health and welfare" src="../../images/eng/common/logo.gif"/></a></h1>
<div class="kor_sym">
<a href="../../../moi.go.kr/eng/sub/a03/nationalSymbol/d5a2e22490af7d4414516807b47a6064" target="_blank" title="new browser"><img alt="National Symbols of the Republic of Korea" src="../../images/eng/common/kor_sym_eng.gif"/></a>
</div>
<!-- function -->
<div class="function">
<!-- [Funciton] - ÆùÆ®»çÀÌÁî -->
<div class="unit">
<div class="ft_size">
<button class="plus" onclick="fontSizeWrap.btnPlus();" type="button"><span class="hide">expand</span></button>
<button class="minus" onclick="fontSizeWrap.btnMinus();" type="button"><span class="hide">reduce</span></button>
<span class="Font_Size"><span class="hide">Font Size</span></span>
</div>
<script type="text/javascript">var fontSizeWrap = new fontSize();</script>
<!-- //[Funciton] - ÆùÆ®»çÀÌÁî -->
<!-- ¾ð¾îº° ¸µÅ© -->
<ul class="global_language">
<li class="mobile"><a href="../../m_eng/50b06ecdc2a14f90913d780c3460fca4" target="_blank" title="new browser"><span class="hide">Mobile</span></a></li>
<li class="Korean"><a href="../../front_new/647a6a76a15a5a8bfc6d5f73d0d9d4d1" target="_blank" title="new browser"><span class="hide">Korean</span></a></li>
<li class="sitemap"><a href="../cs/38f03257ef34df8e601ed2e794b4f84f"><span class="hide">sitemap</span></a></li>
<li class="a-z"><a href="../cs/1001c96bb6754f09ed925f7b6d593bf7"><span class="hide">A-Z Index</span></a></li>
</ul>
<!-- //¾ð¾îº° ¸µÅ© -->
<!-- ¸Þ´º¼³Á¤ -->
<div class="mnsetup">
<div class="btnsetup"><a class="btnms" href="#msetup_layer" id="svcmore_h"><span class="hide">my menu</span></a></div>
<div class="msetup_layer" id="msetup_layer">
<h2>
<img alt="Menu setup" src="../../images/eng/main/musetup.gif"/>
</h2>
<div class="mnsetup_cont">
<ul class="list" id="fmenu"><li>My menu list</li></ul>
</div>
<div class="cg_contwrap">
<div class="cg_cont">
<!-- ÀüÃ¼¸ñ·Ï -->
<ul class="ms_category">
<li>
<input class="input-check" id="mw_100103" name="setmenu" type="checkbox" value="/eng/sg/ssg0103mn.jsp?PAR_MENU_ID=1001&amp;MENU_ID=100103|100103|Organization"/>
<label for="mw_100103">Organization</label>
</li>
<li>
<input class="input-check" id="mw_100113" name="setmenu" type="checkbox" value="/eng/sg/ssg0101mn.jsp?PAR_MENU_ID=1001&amp;MENU_ID=100113|100113|Contact Us"/>
<label for="mw_100113">Contact Us</label>
</li>
<li>
<input class="input-check" id="mw_100105" name="setmenu" type="checkbox" value="/eng/sg/ssg0105mn.jsp?PAR_MENU_ID=1001&amp;MENU_ID=100105|100105|Minister's Profile"/>
<label for="mw_100105">Minister's Profile</label>
</li>
<li>
<input class="input-check" id="mw_100111" name="setmenu" type="checkbox" value="/eng/sg/ssg0111ls.jsp?PAR_MENU_ID=1001&amp;MENU_ID=100111|100111|Press Release"/>
<label for="mw_100111">Press Release</label>
</li>
<li>
<input class="input-check" id="mw_10031801" name="setmenu" type="checkbox" value="/eng/jc/sjc0101mn.jsp?PAR_MENU_ID=1003&amp;MENU_ID=10031801|10031801|Policies"/>
<label for="mw_10031801">Policies</label>
</li>
<li>
<input class="input-check" id="mw_100408" name="setmenu" type="checkbox" value="/eng/cs/scs0301mn.jsp?PAR_MENU_ID=1004&amp;MENU_ID=100408|100408|RSS"/>
<label for="mw_100408">RSS</label>
</li>
<li>
<input class="input-check" id="mw_100410" name="setmenu" type="checkbox" value="/eng/cs/scs0301mn.jsp?PAR_MENU_ID=1004&amp;MENU_ID=100410|100410|Privacy Guideline"/>
<label for="mw_100410">Privacy Guideline</label>
</li>
<li>
<input class="input-check" id="mw_100404" name="setmenu" type="checkbox" value="/eng/cs/scs0301mn.jsp?PAR_MENU_ID=1004&amp;MENU_ID=100404|100404|Users Guide"/>
<label for="mw_100404">Users Guide</label>
</li>
</ul>
<!-- //ÀüÃ¼¸ñ·Ï -->
</div>
<!-- ¹öÆ° Á¤·Ä -->
<div class="btn_msetup">
<p class="left"><input alt="default" class="input-image" id="mymenu_default" src="/images/eng/btn/btn_base.gif" type="image"/></p>
<span class="cg_msg">User can personalize the website</span>
<p class="center">
<input alt="confirm" class="input-image" id="mymenu_set" src="/images/eng/btn/btn_confirm.gif" type="image"/>
<!--a href="#" id="mymenu_set" ><img src="/images/front/btn/btn_confirm.gif" alt="È®ÀÎ" /></a-->
<input alt="cancel" class="input-image" id="mymenu_cancel" src="/images/eng/btn/btn_cancel.gif" type="image"/>
</p>
<p class="right"><a href="../cs/38f03257ef34df8e601ed2e794b4f84f">sitemap</a></p>
</div>
<!-- //¹öÆ° Á¤·Ä -->
</div>
<p class="btn-more"><button class="msbtn_close" id="msbtn_close" type="button"><span class="hide">close</span></button></p>
</div>
</div>
<!-- //¸Þ´º¼³Á¤ -->
<!-- °Ë»ö -->
<!-- 

					<div class="search">

						<form method="post" name="fmSearch" action="/eng/cs/scs0401ls.jsp" onsubmit="return searchCommon(this)" >

							<input type="hidden" name="PAR_MENU_ID" value="1004" />

							<input type="hidden" name="MENU_ID" value="100406" />

							<input type="hidden" name="SEARCHKEY" value="TITLE" />				

							<fieldset>

								<legend>search</legend>

								<label for="SEARCHVALUE" class="hide">search value</label>

								<input type="text" id="SEARCHVALUE" name="SEARCHVALUE" class="input-text" />

								<input type="image" class="input-image" src="/images/eng/common/tl_btnsearch.gif" alt="search" />

							</fieldset>

						</form>

					</div>

					 -->
<!-- //°Ë»ö -->
</div><!-- //unit -->
</div>
<!-- //function -->
</div>
<!-- //header -->
</div>
<!-- //head -->
<hr/>
<!-- spot main -->
<div id="spot-sub">
<img alt="A life-long friend who stands by the public" src="../../images/front_eng/sg/img_head_sg.jpg"/>
</div>
<!-- //spot main -->
<hr/>
<!-- container -->
<div class="clear" id="container">
<div id="subwrap">
<!-- snb -->
<div id="snb">
<h2><a href="616feca8de871f8a1f1e040342b5d550"><img alt="About MW" src="../../images/front_eng/title/h2_am.gif"/></a></h2>
<ul id="snbMenu1">
<li><a href="616feca8de871f8a1f1e040342b5d550"><img alt="Vision &amp; Mission" src="../../images/front_eng/title/left_am01.gif"/></a>
</li>
<li><a href="93dae7d73a99735630654fc2fb46a9eb"><img alt="Organization" src="../../images/front_eng/title/left_am02.gif"/></a>
</li>
<li><a href="482124899dc6a43227599ea28a921fea"><img alt="Contact Us" src="../../images/front_eng/title/left_am03.gif"/></a>
</li>
<li><a href="2d75b746f82cbae41316bd3da4ceb30d"><img alt="Minister¡¯s Profile" src="../../images/front_eng/title/left_am04.gif"/></a>
</li>
<li><a href="a2fde158a68020769e116fe2815d95aa"><img alt="Vice Minister¡¯s Profile" src="../../images/front_eng/title/left_am05.gif"/></a>
</li>
<li><a href="8c6914a853d28a0cf2ce417c6d5fe3ce"><img alt="Past Ministers &amp; Vice Ministers" src="../../images/front_eng/title/left_am06.gif"/></a>
</li>
<li><a href="a79fdae6ffae612a0b5f784645afb1db"><img alt="Location" src="../../images/front_eng/title/left_am07.gif"/></a>
</li>
<li class="on"><a href="76b19fd6a92fcb216e55a4e9dea9a4c8"><img alt="Press Release" src="../../images/front_eng/title/left_am08_over.gif"/></a>
</li>
<li><a href="ea8a1ea6f8dcdcb2b03b8ebc89df5ef6"><img alt="129 Call Center" src="../../images/front_eng/title/left_am09.gif"/></a>
</li>
<li><a href="../../../www.epeople.go.kr/jsp/user/on/eng/ebb342dee28c17242d927d0b1019800f" target="_blank"><img alt="Online Petition" src="../../images/front_eng/title/left_am10.gif"/></a>
</li>
</ul>
<h2><a href="../jc/f397eab66fb162470b191bcc18dfac4f"><img alt="Policies" src="../../images/front_eng/title/h2_pl.gif"/></a></h2>
<ul id="snbMenu2">
<li class="submenu"><img alt="Enhancement of Customized Welfare Services by Life-Cycle Phase" src="../../images/front_new/title/left_pl100321.gif"/>
<ul>
<li><a href="../jc/f397eab66fb162470b191bcc18dfac4f"><img alt="Reinforcement of support for income growth and work opportunities of low-income people" src="../../images/front_new/title/left_pl10032101.gif"/></a></li>
<li><a href="../jc/6d963af417c35f2c3575a2f47d93315d"><img alt="Welfare services reaching out to people and improvement of public perception" src="../../images/front_new/title/left_pl10032102.gif"/></a></li>
<li><a href="../jc/7c117d987132de318dd869c7e15cd6d1"><img alt="Promotion of rights and interests of children, the disabled, the elderly, etc." src="../../images/front_new/title/left_pl10032103.gif"/></a></li>
<li><a href="../jc/3cd7dc5b01d534d90eba055e35cdf386"><img alt="Reduction of burden of medical expenses, and the reorganization of the system for determining health insurance premiums" src="../../images/front_new/title/left_pl10032104.gif"/></a></li>
</ul>
</li>
<li class="submenu"><img alt="Establishment of Health Insurance System centered on People" src="../../images/front_new/title/left_pl100322.gif"/>
<ul>
<li><a href="../jc/6698fa46cb8d35f0f8aeb6f289ab2ce9"><img alt="Reinforcement of patient-oriented medical services" src="../../images/front_new/title/left_pl10032201.gif"/></a></li>
<li><a href="../jc/6194a5e0555dab84754814c541f09b27"><img alt="Strengthening of essential and public health care services and systematic response to infectious diseases" src="../../images/front_new/title/left_pl10032202.gif"/></a></li>
<li><a href="../jc/7603054a50c83c708da6d6702afe3d14"><img alt="Reinforcement of Preventive Health Care" src="../../images/front_new/title/left_pl10032203.gif"/></a></li>
<li><a href="../jc/5975190b9def38149afd3ad48132162f"><img alt="Enhancement of healthcare industry performance and job creation" src="../../images/front_new/title/left_pl10032204.gif"/></a></li>
</ul>
</li>
<li class="submenu"><img alt="Strengthening Responses to Demographic Crisis" src="../../images/front_new/title/left_pl100323.gif"/>
<ul>
<li><a href="../jc/8334fe91b7312eb840b99581e90bc297"><img alt="Establishment of a response system for coping with low birthrate" src="../../images/front_new/title/left_pl10032301.gif"/></a></li>
<li><a href="../jc/687f9bcd11741aea5264c8392dc17ffc"><img alt="Improvement of a system for supporting childbirth and parenting" src="../../images/front_new/title/left_pl10032302.gif"/></a></li>
<li><a href="../jc/d59e41ec8156d3ed1193b5f64629cf85"><img alt="Enhancement of preparation for aging society" src="../../images/front_new/title/left_pl10032303.gif"/></a></li>
</ul>
</li>
</ul>
<h2><a href="../cs/b64cc4894874ba0eb4af154d245908a9"><img alt="Help" src="../../images/front_eng/title/h2_hp.gif"/></a></h2>
<ul id="snbMenu3">
<li><a href="../cs/b64cc4894874ba0eb4af154d245908a9"><img alt="Users Guide" src="../../images/front_eng/title/left_hp01.gif"/></a>
</li>
<li><a href="../cs/81e6dbd0ed113665170a29b899ab0c21"><img alt="Privacy Guideline" src="../../images/front_eng/title/left_hp04.gif"/></a>
</li>
<li><a href="../cs/bab2f9d80d5980695b6081cb22ceb64b"><img alt="RSS" src="../../images/front_eng/title/left_hp03.gif"/></a>
</li>
<li><a href="../cs/38f03257ef34df8e601ed2e794b4f84f"><img alt="Sitemap" src="../../images/front_eng/title/left_hp05.gif"/></a>
</li>
<li><a href="../cs/1001c96bb6754f09ed925f7b6d593bf7"><img alt="A-Z Index" src="../../images/front_eng/title/left_hp06.gif"/></a>
</li>
</ul>
</div>
<script src="../../js/jquery-1.11.0.min.js" type="text/javascript"></script>
<script type="text/javascript">
			$('.submenu').last().find('ul').attr('class', 'noline');
			imgMenuOver("snb");
			
			$(function(){
				$(".on").parents('ul').slideDown();
			});	
			
			$(".submenu").click(function(){
				$(".submenu").not($(this)).children('ul').slideUp();
				$(this).children('ul').slideToggle();
			});
		</script>
<!-- //snb -->
<!-- contents -->
<div id="contents">
<!-- mnvisual - ÄÁÅÙÃ÷ Å¸ÀÌÆ² -->
<div class="mnvisual">
<!-- h2 - Å¸ÀÌÆ² -->
<!-- //h2 - Å¸ÀÌÆ² -->
<!-- location - ÁÖ¼Ò -->
<div id="location"> <a class="home" href="../261f58801c1da21d0b6f7021b30b648b">HOME</a> &gt; <a href="616feca8de871f8a1f1e040342b5d550">ABOUT MOHW</a> &gt; <span class="here">Press Release</span></div>
<!-- //location - ÁÖ¼Ò -->
</div>
<!-- //mnvisual - ÄÁÅÙÃ÷ Å¸ÀÌÆ² -->
<!-- content-area -->
<div class="content-area">
<!-- DB ¿¡¼­ contents µ¥ÀÌÅÍ¸¦ °¡Á®¿Í¼­ »Ñ·ÁÁØ´Ù. -->
<!-- board -->
<form action="ssg0111vw.jsp" method="post" name="fmView">
<input name="PAR_MENU_ID" type="hidden" value="1001"/>
<input name="MENU_ID" type="hidden" value="100111"/>
<input name="page" type="hidden" value="15"/>
<input name="CONT_SEQ" type="hidden" value="289352"/>
<input name="MENU_ID" type="hidden" value="100111"/>
<input name="FILE_SEQ" type="hidden" value=""/>
<input name="SEARCHKEY" type="hidden" value=""/>
<input name="SEARCHVALUE" type="hidden" value=""/>
<!-- table:view -->
<table class="view" summary="ABOUT MOHW &gt; Press Release detail.">
<caption>ABOUT MOHW &gt; Press Release</caption>
<colgroup>
<col width="12%"/><col width="38%"/><col width="12%"/><col width="38%"/>
</colgroup>
<tbody>
<tr>
<th scope="row">Subject</th>
<td colspan="3">Korea¡¯s incrementally modified drug makes its first advancement into the U.S. market</td>
</tr>
<tr>
<th scope="row">Date</th>
<td>2013-08-16</td>
<th scope="row">Hit</th>
<td>5093</td>
</tr>
<tr>
<th scope="row">Contents</th>
<td class="view" colspan="3"><p class="MsoNormal" style="margin: 0cm 0cm 10pt">
<b style="mso-bidi-font-weight: normal"><u><span lang="EN-US" style="font-size: 12pt; line-height: 115%; mso-fareast-font-family: '¸¼Àº °íµñ'; mso-fareast-theme-font: minor-latin"><o:p><span style="text-decoration: none"><font color="#000000" face="¸¼Àº °íµñ"> </font></span></o:p></span></u></b></p>
<p align="center" class="MsoNormal" style="margin: 0cm 0cm 10pt; text-align: center">
<b style="mso-bidi-font-weight: normal"><u><span lang="EN-US" style="font-size: 12pt; line-height: 115%; mso-fareast-font-family: '¸¼Àº °íµñ'; mso-fareast-theme-font: minor-latin"><font color="#000000"><font face="¸¼Àº °íµñ">Korea’s incrementally modified drug makes its first advancement into the U.S. market<o:p></o:p></font></font></span></u></b></p>
<p class="MsoNormal" style="margin: 0cm 0cm 0pt; vertical-align: baseline; word-break: keep-all; line-height: 180%">
<span lang="EN-US" style="line-height: 180%; mso-fareast-font-family: '¸¼Àº °íµñ'; mso-fareast-theme-font: minor-latin; mso-bidi-font-size: 10.0pt; mso-bidi-font-family: ±¼¸²; mso-font-kerning: 0pt"><o:p><font color="#000000" face="¸¼Àº °íµñ" size="2"> </font></o:p></span></p>
<p align="center" class="MsoListParagraph" style="margin: 0cm 0cm 0pt 20pt; vertical-align: baseline; word-break: keep-all; text-indent: -18pt; line-height: 180%; text-align: center; mso-para-margin-top: 0cm; mso-para-margin-right: 0cm; mso-para-margin-bottom: .0001pt; mso-para-margin-left: 0gd; mso-list: l0 level1 lfo1">
<font color="#000000"><span lang="EN-US" style="line-height: 180%; mso-fareast-font-family: '¸¼Àº °íµñ'; mso-bidi-font-size: 10.0pt; mso-ascii-font-family: '¸¼Àº °íµñ'; mso-hansi-font-family: '¸¼Àº °íµñ'; mso-bidi-font-family: '¸¼Àº °íµñ'; mso-font-kerning: 0pt"><span style="mso-list: ignore"><font face="¸¼Àº °íµñ" size="2">-</font><span style="font: 7pt 'times new roman'">       </span></span></span><span lang="EN-US" style="line-height: 180%; mso-fareast-font-family: '¸¼Àº °íµñ'; mso-fareast-theme-font: minor-latin; mso-bidi-font-size: 10.0pt; mso-bidi-font-family: ±¼¸²; mso-font-kerning: 0pt"><font size="2"><font face="¸¼Àº °íµñ">Hanmi pharmaceutical company’s Esomezol gains U.S. FDA approval for the first time as an incrementally modified drug, and is expected to become a stepping stone to enter the U.S. market which is worth 6 billion dollars - <o:p></o:p></font></font></span></font></p>
<p class="MsoNormal" style="margin: 0cm 0cm 0pt; vertical-align: baseline; word-break: keep-all; line-height: 180%">
<span lang="EN-US" style="line-height: 180%; mso-fareast-font-family: '¸¼Àº °íµñ'; mso-fareast-theme-font: minor-latin; mso-bidi-font-size: 10.0pt; mso-bidi-font-family: ±¼¸²; mso-font-kerning: 0pt"><o:p><font color="#000000" face="¸¼Àº °íµñ" size="2"> </font></o:p></span></p>
<p class="MsoNormal" style="margin: 0cm 0cm 0pt; vertical-align: baseline; word-break: keep-all; line-height: 180%">
<span lang="EN-US" style="line-height: 180%; mso-fareast-font-family: '¸¼Àº °íµñ'; mso-fareast-theme-font: minor-latin; mso-bidi-font-size: 10.0pt; mso-bidi-font-family: ±¼¸²; mso-font-kerning: 0pt"><font size="2"><font color="#000000"><font face="¸¼Àº °íµñ">For the first time, a Korean made incrementally modified drug will advance into the U.S. market, the largest pharmaceutical market in the world. <o:p></o:p></font></font></font></span></p>
<p class="MsoNormal" style="margin: 0cm 0cm 0pt; vertical-align: baseline; word-break: keep-all; line-height: 180%">
<span lang="EN-US" style="line-height: 180%; mso-fareast-font-family: '¸¼Àº °íµñ'; mso-fareast-theme-font: minor-latin; mso-bidi-font-size: 10.0pt; mso-bidi-font-family: ±¼¸²; mso-font-kerning: 0pt"><o:p><font color="#000000" face="¸¼Àº °íµñ" size="2"> </font></o:p></span></p>
<p class="MsoNormal" style="margin: 0cm 0cm 0pt; vertical-align: baseline; word-break: keep-all; line-height: 180%">
<span lang="EN-US" style="line-height: 180%; mso-fareast-font-family: '¸¼Àº °íµñ'; mso-fareast-theme-font: minor-latin; mso-bidi-font-size: 10.0pt; mso-bidi-font-family: ±¼¸²; mso-font-kerning: 0pt"><font size="2"><font color="#000000"><font face="¸¼Àº °íµñ">The Ministry of Health and Welfare (Minister Chin Young) said that the “Esomezol capsule,” a reflux esophagitis drug made by Hanmi Pharm. Co., Ltd. acquired marketing authorization from the U.S. Food and Drug Administration (FDA) on August 6<sup>th</sup> (U.S. local time) for the first time as a Korean developed incrementally modified drug. <o:p></o:p></font></font></font></span></p>
<p class="MsoNormal" style="margin: 0cm 0cm 0pt; vertical-align: baseline; word-break: keep-all; line-height: 180%">
<span lang="EN-US" style="line-height: 180%; mso-fareast-font-family: '¸¼Àº °íµñ'; mso-fareast-theme-font: minor-latin; mso-bidi-font-size: 10.0pt; mso-bidi-font-family: ±¼¸²; mso-font-kerning: 0pt"><o:p><font color="#000000" face="¸¼Àº °íµñ" size="2"> </font></o:p></span></p>
<p class="MsoNormal" style="margin: 0cm 0cm 0pt; vertical-align: baseline; word-break: keep-all; line-height: 180%">
<span lang="EN-US" style="line-height: 180%; mso-fareast-font-family: '¸¼Àº °íµñ'; mso-fareast-theme-font: minor-latin; mso-bidi-font-size: 10.0pt; mso-bidi-font-family: ±¼¸²; mso-font-kerning: 0pt"><font size="2"><font color="#000000"><font face="¸¼Àº °íµñ"><span style="mso-spacerun: yes">   </span>* The North American market which includes the U.S. accounts for 37% of the entire global pharmaceutical market (worth 370 trillion won). <o:p></o:p></font></font></font></span></p>
<p class="MsoNormal" style="margin: 0cm 0cm 0pt; vertical-align: baseline; word-break: keep-all; line-height: 180%">
<span lang="EN-US" style="line-height: 180%; mso-fareast-font-family: '¸¼Àº °íµñ'; mso-fareast-theme-font: minor-latin; mso-bidi-font-size: 10.0pt; mso-bidi-font-family: ±¼¸²; mso-font-kerning: 0pt"><o:p><font color="#000000" face="¸¼Àº °íµñ" size="2"> </font></o:p></span></p>
<p class="MsoNormal" style="margin: 0cm 0cm 0pt; vertical-align: baseline; word-break: keep-all; line-height: 180%">
<span lang="EN-US" style="line-height: 180%; mso-fareast-font-family: '¸¼Àº °íµñ'; mso-fareast-theme-font: minor-latin; mso-bidi-font-size: 10.0pt; mso-bidi-font-family: ±¼¸²; mso-font-kerning: 0pt"><font size="2"><font color="#000000"><font face="¸¼Àº °íµñ">So far, the U.S. FDA granted marketing authorization to Factive (by LG Life Sciences) in 2003, the 5<sup>th</sup> drug to be developed in Korea (approved in Korea on December 27<sup>th</sup>, 2002), and Valtropin (somatotropin by LG Life Sciences) in 2007. <o:p></o:p></font></font></font></span></p>
<p class="MsoNormal" style="margin: 0cm 0cm 0pt; vertical-align: baseline; word-break: keep-all; line-height: 180%">
<span lang="EN-US" style="line-height: 180%; mso-fareast-font-family: '¸¼Àº °íµñ'; mso-fareast-theme-font: minor-latin; mso-bidi-font-size: 10.0pt; mso-bidi-font-family: ±¼¸²; mso-font-kerning: 0pt"><o:p><font color="#000000" face="¸¼Àº °íµñ" size="2"> </font></o:p></span></p>
<p class="MsoNormal" style="margin: 0cm 0cm 0pt; vertical-align: baseline; word-break: keep-all; line-height: 180%">
<span lang="EN-US" style="line-height: 180%; mso-fareast-font-family: '¸¼Àº °íµñ'; mso-fareast-theme-font: minor-latin; mso-bidi-font-size: 10.0pt; mso-bidi-font-family: ±¼¸²; mso-font-kerning: 0pt"><font size="2"><font color="#000000"><font face="¸¼Àº °íµñ"><span style="mso-spacerun: yes">   </span>* Valtropin (somatotropin) was granted marketing authorization by the U.S. FDA but has not yet entered the market. <o:p></o:p></font></font></font></span></p>
<p class="MsoNormal" style="margin: 0cm 0cm 0pt; vertical-align: baseline; word-break: keep-all; line-height: 180%">
<span lang="EN-US" style="line-height: 180%; mso-fareast-font-family: '¸¼Àº °íµñ'; mso-fareast-theme-font: minor-latin; mso-bidi-font-size: 10.0pt; mso-bidi-font-family: ±¼¸²; mso-font-kerning: 0pt"><o:p><font color="#000000" face="¸¼Àº °íµñ" size="2"> </font></o:p></span></p>
<p class="MsoNormal" style="margin: 0cm 0cm 0pt; vertical-align: baseline; word-break: keep-all; line-height: 180%">
<span lang="EN-US" style="line-height: 180%; mso-fareast-font-family: '¸¼Àº °íµñ'; mso-fareast-theme-font: minor-latin; mso-bidi-font-size: 10.0pt; mso-bidi-font-family: ±¼¸²; mso-font-kerning: 0pt"><font size="2"><font color="#000000"><font face="¸¼Àº °íµñ">Esomezol is an incrementally modified drug of the Nexium tablet (Astrazeneca), the No. 1 prescribed drug in the U.S. with 6 billion dollars of sales in 2012 (source: IMS). <o:p></o:p></font></font></font></span></p>
<p class="MsoNormal" style="margin: 0cm 0cm 0pt; vertical-align: baseline; word-break: keep-all; line-height: 180%">
<span lang="EN-US" style="line-height: 180%; mso-fareast-font-family: '¸¼Àº °íµñ'; mso-fareast-theme-font: minor-latin; mso-bidi-font-size: 10.0pt; mso-bidi-font-family: ±¼¸²; mso-font-kerning: 0pt"><o:p><font color="#000000" face="¸¼Àº °íµñ" size="2"> </font></o:p></span></p>
<p class="MsoNormal" style="margin: 0cm 0cm 0pt; vertical-align: baseline; word-break: keep-all; line-height: 180%">
<span lang="EN-US" style="line-height: 180%; mso-fareast-font-family: '¸¼Àº °íµñ'; mso-fareast-theme-font: minor-latin; mso-bidi-font-size: 10.0pt; mso-bidi-font-family: ±¼¸²; mso-font-kerning: 0pt"><font size="2"><font color="#000000"><font face="¸¼Àº °íµñ">Marketing authorization resulted from a recent mutual agreement reached after a two-year-long patent lawsuit between Astrazeneca and Hanmi which sought for approval to sell the product. <o:p></o:p></font></font></font></span></p>
<p class="MsoNormal" style="margin: 0cm 0cm 0pt; vertical-align: baseline; word-break: keep-all; line-height: 180%">
<span lang="EN-US" style="line-height: 180%; mso-fareast-font-family: '¸¼Àº °íµñ'; mso-fareast-theme-font: minor-latin; mso-bidi-font-size: 10.0pt; mso-bidi-font-family: ±¼¸²; mso-font-kerning: 0pt"><o:p><font color="#000000" face="¸¼Àº °íµñ" size="2"> </font></o:p></span></p>
<p class="MsoNormal" style="margin: 0cm 0cm 0pt; vertical-align: baseline; word-break: keep-all; line-height: 180%">
<span lang="EN-US" style="line-height: 180%; mso-fareast-font-family: '¸¼Àº °íµñ'; mso-fareast-theme-font: minor-latin; mso-bidi-font-size: 10.0pt; mso-bidi-font-family: ±¼¸²; mso-font-kerning: 0pt"><font size="2"><font color="#000000"><font face="¸¼Àº °íµñ"><span style="mso-spacerun: yes">   </span>* The lawsuit took place in the New Jersey District Court in June, 2013, ending with an agreement that Esomezol did not infringe on the patent of Nexium. <o:p></o:p></font></font></font></span></p>
<p class="MsoNormal" style="margin: 0cm 0cm 0pt; vertical-align: baseline; word-break: keep-all; line-height: 180%">
<span lang="EN-US" style="line-height: 180%; mso-fareast-font-family: '¸¼Àº °íµñ'; mso-fareast-theme-font: minor-latin; mso-bidi-font-size: 10.0pt; mso-bidi-font-family: ±¼¸²; mso-font-kerning: 0pt"><o:p><font color="#000000" face="¸¼Àº °íµñ" size="2"> </font></o:p></span></p>
<p class="MsoNormal" style="margin: 0cm 0cm 0pt; vertical-align: baseline; word-break: keep-all; line-height: 180%">
<span lang="EN-US" style="line-height: 180%; mso-fareast-font-family: '¸¼Àº °íµñ'; mso-fareast-theme-font: minor-latin; mso-bidi-font-size: 10.0pt; mso-bidi-font-family: ±¼¸²; mso-font-kerning: 0pt"><font size="2"><font color="#000000"><font face="¸¼Àº °íµñ">This is the first case of overturning the U.S. Hatch-Waxman Act that connects approvals with patents. <o:p></o:p></font></font></font></span></p>
<p class="MsoNormal" style="margin: 0cm 0cm 0pt; vertical-align: baseline; word-break: keep-all; line-height: 180%">
<span lang="EN-US" style="line-height: 180%; mso-fareast-font-family: '¸¼Àº °íµñ'; mso-fareast-theme-font: minor-latin; mso-bidi-font-size: 10.0pt; mso-bidi-font-family: ±¼¸²; mso-font-kerning: 0pt"><o:p><font color="#000000" face="¸¼Àº °íµñ" size="2"> </font></o:p></span></p>
<p class="MsoNormal" style="margin: 0cm 0cm 0pt; vertical-align: baseline; word-break: keep-all; line-height: 180%">
<span lang="EN-US" style="line-height: 180%; mso-fareast-font-family: '¸¼Àº °íµñ'; mso-fareast-theme-font: minor-latin; mso-bidi-font-size: 10.0pt; mso-bidi-font-family: ±¼¸²; mso-font-kerning: 0pt"><font size="2"><font color="#000000"><font face="¸¼Àº °íµñ"><span style="mso-spacerun: yes">   </span>* Once a pharmaceutical company applies for marketing approval of generic drugs, the U.S. FDA proceeds with a New Drug Application only when an original patent holder is notified of the application and does not have objection. In the case of a patent infringement lawsuit, the application process can be suspended, and the original patent holding company can postpone the launching of the generic drug or incrementally modified drug for up to 30 months. <o:p></o:p></font></font></font></span></p>
<p class="MsoNormal" style="margin: 0cm 0cm 0pt; vertical-align: baseline; word-break: keep-all; line-height: 180%">
<span lang="EN-US" style="line-height: 180%; mso-fareast-font-family: '¸¼Àº °íµñ'; mso-fareast-theme-font: minor-latin; mso-bidi-font-size: 10.0pt; mso-bidi-font-family: ±¼¸²; mso-font-kerning: 0pt"><o:p><font color="#000000" face="¸¼Àº °íµñ" size="2"> </font></o:p></span></p>
<p class="MsoNormal" style="margin: 0cm 0cm 0pt; vertical-align: baseline; word-break: keep-all; line-height: 180%">
<span lang="EN-US" style="line-height: 180%; mso-fareast-font-family: '¸¼Àº °íµñ'; mso-fareast-theme-font: minor-latin; mso-bidi-font-size: 10.0pt; mso-bidi-font-family: ±¼¸²; mso-font-kerning: 0pt"><font size="2"><font color="#000000"><font face="¸¼Àº °íµñ">As a result, Hanmi is expected to become the sole seller in the market until May, 2014 when the expiration of the Nexium patent ends.<o:p></o:p></font></font></font></span></p>
<p class="MsoNormal" style="margin: 0cm 0cm 0pt; vertical-align: baseline; word-break: keep-all; line-height: 180%">
<span lang="EN-US" style="line-height: 180%; mso-fareast-font-family: '¸¼Àº °íµñ'; mso-fareast-theme-font: minor-latin; mso-bidi-font-size: 10.0pt; mso-bidi-font-family: ±¼¸²; mso-font-kerning: 0pt"><o:p><font color="#000000" face="¸¼Àº °íµñ" size="2"> </font></o:p></span></p>
<p class="MsoNormal" style="margin: 0cm 0cm 0pt; vertical-align: baseline; word-break: keep-all; line-height: 180%">
<span lang="EN-US" style="line-height: 180%; mso-fareast-font-family: '¸¼Àº °íµñ'; mso-fareast-theme-font: minor-latin; mso-bidi-font-size: 10.0pt; mso-bidi-font-family: ±¼¸²; mso-font-kerning: 0pt"><font size="2"><font color="#000000"><font face="¸¼Àº °íµñ">- Esomezol will soon hit the shelves in the U.S. through the partnership of Amneal Pharmaceuticals under the name of Esomeprazole strontium. <o:p></o:p></font></font></font></span></p>
<p class="MsoNormal" style="margin: 0cm 0cm 0pt; vertical-align: baseline; word-break: keep-all; line-height: 180%">
<span lang="EN-US" style="line-height: 180%; mso-fareast-font-family: '¸¼Àº °íµñ'; mso-fareast-theme-font: minor-latin; mso-bidi-font-size: 10.0pt; mso-bidi-font-family: ±¼¸²; mso-font-kerning: 0pt"><o:p><font color="#000000" face="¸¼Àº °íµñ" size="2"> </font></o:p></span></p>
<p class="MsoNormal" style="margin: 0cm 0cm 0pt; vertical-align: baseline; word-break: keep-all; line-height: 180%">
<span lang="EN-US" style="line-height: 180%; mso-fareast-font-family: '¸¼Àº °íµñ'; mso-fareast-theme-font: minor-latin; mso-bidi-font-size: 10.0pt; mso-bidi-font-family: ±¼¸²; mso-font-kerning: 0pt"><font size="2"><font color="#000000"><font face="¸¼Àº °íµñ">The Ministry of Health and Welfare said that Esomezol’s challenge to the U.S. market is a great example for other Korean pharmaceutical companies. <o:p></o:p></font></font></font></span></p>
<p class="MsoNormal" style="margin: 0cm 0cm 0pt; vertical-align: baseline; word-break: keep-all; line-height: 180%">
<span lang="EN-US" style="line-height: 180%; mso-fareast-font-family: '¸¼Àº °íµñ'; mso-fareast-theme-font: minor-latin; mso-bidi-font-size: 10.0pt; mso-bidi-font-family: ±¼¸²; mso-font-kerning: 0pt"><o:p><font color="#000000" face="¸¼Àº °íµñ" size="2"> </font></o:p></span></p>
<p class="MsoNormal" style="margin: 0cm 0cm 0pt; vertical-align: baseline; word-break: keep-all; line-height: 180%">
<span lang="EN-US" style="line-height: 180%; mso-fareast-font-family: '¸¼Àº °íµñ'; mso-fareast-theme-font: minor-latin; mso-bidi-font-size: 10.0pt; mso-bidi-font-family: ±¼¸²; mso-font-kerning: 0pt"><font size="2"><font color="#000000"><font face="¸¼Àº °íµñ">The drug is also expected to not only be competitive but commercially successful in the world’s largest U.S. market due to its reasonable pricing and high quality.<o:p></o:p></font></font></font></span></p>
<p class="MsoNormal" style="margin: 0cm 0cm 0pt; vertical-align: baseline; word-break: keep-all; line-height: 180%">
<span lang="EN-US" style="line-height: 180%; mso-fareast-font-family: '¸¼Àº °íµñ'; mso-fareast-theme-font: minor-latin; mso-bidi-font-size: 10.0pt; mso-bidi-font-family: ±¼¸²; mso-font-kerning: 0pt"><o:p><font color="#000000" face="¸¼Àº °íµñ" size="2"> </font></o:p></span></p>
<p class="MsoNormal" style="margin: 0cm 0cm 0pt; vertical-align: baseline; word-break: keep-all; line-height: 180%">
<span lang="EN-US" style="line-height: 180%; mso-fareast-font-family: '¸¼Àº °íµñ'; mso-fareast-theme-font: minor-latin; mso-bidi-font-size: 10.0pt; mso-bidi-font-family: ±¼¸²; mso-font-kerning: 0pt"><font size="2"><font color="#000000"><font face="¸¼Àº °íµñ">The ministry added that this advancement is meaningful in that Korea has secured a bridgehead to enter the North American market, the largest pharmaceutical market in the world, through the government-private joint “Columbus Project (2011-2012).” <o:p></o:p></font></font></font></span></p>
<p class="MsoNormal" style="margin: 0cm 0cm 0pt; vertical-align: baseline; word-break: keep-all; line-height: 180%">
<span lang="EN-US" style="line-height: 180%; mso-fareast-font-family: '¸¼Àº °íµñ'; mso-fareast-theme-font: minor-latin; mso-bidi-font-size: 10.0pt; mso-bidi-font-family: ±¼¸²; mso-font-kerning: 0pt"><o:p><font color="#000000" face="¸¼Àº °íµñ" size="2"> </font></o:p></span></p>
<p class="MsoNormal" style="margin: 0cm 0cm 0pt; vertical-align: baseline; word-break: keep-all; line-height: 180%">
<span lang="EN-US" style="line-height: 180%; mso-fareast-font-family: '¸¼Àº °íµñ'; mso-fareast-theme-font: minor-latin; mso-bidi-font-size: 10.0pt; mso-bidi-font-family: ±¼¸²; mso-font-kerning: 0pt"><font size="2"><font color="#000000"><font face="¸¼Àº °íµñ"><span style="mso-spacerun: yes">   </span>* The government selected 42 companies (22 pharmaceuticals, 17 medical equipment makers, and 3 cosmetic companies) and offered customized support related to approval and global marketing → secured a bridgehead to enter the U.S. market by helping with the Investigational New Drug Application of the U.S. FDA. <o:p></o:p></font></font></font></span></p>
<p class="MsoNormal" style="margin: 0cm 0cm 0pt; vertical-align: baseline; word-break: keep-all; line-height: 180%">
<span lang="EN-US" style="line-height: 180%; mso-fareast-font-family: '¸¼Àº °íµñ'; mso-fareast-theme-font: minor-latin; mso-bidi-font-size: 10.0pt; mso-bidi-font-family: ±¼¸²; mso-font-kerning: 0pt"><o:p><font color="#000000" face="¸¼Àº °íµñ" size="2"> </font></o:p></span></p>
<p class="MsoNormal" style="margin: 0cm 0cm 0pt; vertical-align: baseline; word-break: keep-all; line-height: 180%">
<span lang="EN-US" style="line-height: 180%; mso-fareast-font-family: '¸¼Àº °íµñ'; mso-fareast-theme-font: minor-latin; mso-bidi-font-size: 10.0pt; mso-bidi-font-family: ±¼¸²; mso-font-kerning: 0pt"><font size="2"><font color="#000000"><font face="¸¼Àº °íµñ">An official from the ministry said that a substantial number of products from LG Life Sciences and Dong-A Pharmaceutical will complete clinical tests in the U.S. and begin hitting the U.S. market within this year. <o:p></o:p></font></font></font></span></p>
<p class="MsoNormal" style="margin: 0cm 0cm 0pt; vertical-align: baseline; word-break: keep-all; line-height: 180%">
<span lang="EN-US" style="line-height: 180%; mso-fareast-font-family: '¸¼Àº °íµñ'; mso-fareast-theme-font: minor-latin; mso-bidi-font-size: 10.0pt; mso-bidi-font-family: ±¼¸²; mso-font-kerning: 0pt"><o:p><font color="#000000" face="¸¼Àº °íµñ" size="2"> </font></o:p></span></p>
<p class="MsoNormal" style="margin: 0cm 0cm 0pt; vertical-align: baseline; word-break: keep-all; line-height: 180%">
<span lang="EN-US" style="line-height: 180%; mso-fareast-font-family: '¸¼Àº °íµñ'; mso-fareast-theme-font: minor-latin; mso-bidi-font-size: 10.0pt; mso-bidi-font-family: ±¼¸²; mso-font-kerning: 0pt"><font size="2"><font color="#000000"><font face="¸¼Àº °íµñ">Recently, more Korean pharmaceutical companies have advanced into foreign markets such as the pharmaceutical company Celltrion receiving positive opinions for their newly developed biosimilar Remsima (rheumatism arthritis treatment) from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use for sale in the European Union (June, 2013); JW Pharmaceutical that signed an export contract for a Triple-Chamber Bag for Nutrition with Baxter (July, 2013); and Boryung Pharmaceutical Company which signed an export contract for the Kanarb Tab. with Central and South American countries (July, 2013). <o:p></o:p></font></font></font></span></p>
<p class="MsoNormal" style="margin: 0cm 0cm 0pt; vertical-align: baseline; word-break: keep-all; line-height: 180%">
<span lang="EN-US" style="line-height: 180%; mso-fareast-font-family: '¸¼Àº °íµñ'; mso-fareast-theme-font: minor-latin; mso-bidi-font-size: 10.0pt; mso-bidi-font-family: ±¼¸²; mso-font-kerning: 0pt"><o:p><font color="#000000" face="¸¼Àº °íµñ" size="2"> </font></o:p></span></p>
<p class="MsoNormal" style="margin: 0cm 0cm 0pt; vertical-align: baseline; word-break: keep-all; line-height: 180%">
<span lang="EN-US" style="line-height: 180%; mso-fareast-font-family: '¸¼Àº °íµñ'; mso-fareast-theme-font: minor-latin; mso-bidi-font-size: 10.0pt; mso-bidi-font-family: ±¼¸²; mso-font-kerning: 0pt"><font size="2"><font color="#000000"><font face="¸¼Àº °íµñ">The ministry official added that these companies are spreading the hope of advancement into global markets to the entire Korean pharmaceutical industry, and thus this year is expected to become an important period for the growth of the industry. <o:p></o:p></font></font></font></span></p>
<p class="MsoNormal" style="margin: 0cm 0cm 0pt; vertical-align: baseline; word-break: keep-all; line-height: 180%">
<span lang="EN-US" style="line-height: 180%; mso-fareast-font-family: '¸¼Àº °íµñ'; mso-fareast-theme-font: minor-latin; mso-bidi-font-size: 10.0pt; mso-bidi-font-family: ±¼¸²; mso-font-kerning: 0pt"><o:p><font color="#000000" face="¸¼Àº °íµñ" size="2"> </font></o:p></span></p>
<p class="MsoNormal" style="margin: 0cm 0cm 0pt; vertical-align: baseline; word-break: keep-all; line-height: 180%">
<span lang="EN-US" style="line-height: 180%; mso-fareast-font-family: '¸¼Àº °íµñ'; mso-fareast-theme-font: minor-latin; mso-bidi-font-size: 10.0pt; mso-bidi-font-family: ±¼¸²; mso-font-kerning: 0pt"><font size="2"><font color="#000000"><font face="¸¼Àº °íµñ">As the government revealed in its five-year initiatives of supporting the pharmaceutical industry to realize the government’s future plans, the official stressed that the ministry recognizes that the pharmaceutical industry is the core of the nation’s creative economy, and will unsparingly support the industry to help it develop new medicines and advance into foreign markets, and ultimately become the core growth industry in the future. <o:p></o:p></font></font></font></span></p></td>
</tr>
<tr>
<th scope="row">File</th>
<td colspan="3">
<p><img alt="" src="../../images/common/file/icon_file.gif"/> <a href="../../../download.mohw.go.kr/front_new/modules/36f2973f561fb94a7f6b023786908039">[ENG][8.7]Korea¡¯s_incrementally_modified_drug_makes_its_first_advancement_into_the_U.S._market.docx (48 KB / Download : 718)</a></p>
</td>
</tr>
</tbody>
</table>
<!-- /table:view -->
<!-- ÇÏ´Ü ¹öÆ° ¿µ¿ª -->
<div class="btn btm">
<!--  ¿À¸¥ ÂÊ ¿µ¿ª ¹öÆ° -->
<a href="69279edea38f89c531ee92dcc558f429"><img alt="list" class="right" src="../../images/eng/common/btn_list.gif"/></a>
<!--  /¿À¸¥ ÂÊ ¿µ¿ª ¹öÆ° -->
</div>
<!-- /ÇÏ´Ü ¹öÆ° ¿µ¿ª -->
</form>
<br/>
<br/>
<div class="view_list">
<form action="ssg0111ls.jsp" method="post" name="fmList">
<input name="PAR_MENU_ID" type="hidden" value="1001"/>
<input name="MENU_ID" type="hidden" value="100111"/>
<input name="page" type="hidden" value="15"/>
<input name="SEARCHKEY" type="hidden" value=""/>
<input name="SEARCHVALUE" type="hidden" value=""/>
<input name="CONT_SEQ" type="hidden" value=""/>
<!-- table head above list -->
<div id="tablehead">
<p>Total <strong>345</strong> Articles</p>
</div>
<!-- /table head above list -->
<table class="list" summary="Publication list.">
<caption>Publication</caption>
<colgroup>
<col width="8%"/><col width="60%"/>
<col width="16%"/><col width="8%"/><col width="8%"/>
</colgroup>
<thead>
<tr>
<th class="first" scope="col">No</th>
<th scope="col">Subject</th>
<th scope="col">Date</th>
<th scope="col">File</th>
<th scope="col">Hit</th>
</tr>
</thead>
<tbody>
<tr>
<td>205</td>
<td class="left"><a href="d212da4cc364d67ddc07b8e71f241a54">Press Release Summary (June 22)</a></td>
<td>2015-06-22</td>
<td><img alt="file" src="../../images/eng/common/icon_file.gif"/></td>
<td>1911</td>
</tr>
<tr>
<td>204</td>
<td class="left"><a href="64d92272b5170388c66a1280ec815bda">The Ministry Designates MERS Hospital</a></td>
<td>2015-06-22</td>
<td><img alt="file" src="../../images/eng/common/icon_file.gif"/></td>
<td>1489</td>
</tr>
<tr>
<td>203</td>
<td class="left"><a href="e089b8c7127913c10030c390e03b02c3">Hospitals with Known MERS Exposure (June 22)</a></td>
<td>2015-06-22</td>
<td><img alt="file" src="../../images/eng/common/icon_file.gif"/></td>
<td>1855</td>
</tr>
<tr>
<td>202</td>
<td class="left"><a href="f3782c5996c86af00382db58cd0fca8f">MERS Statistics (June 22)</a></td>
<td>2015-06-22</td>
<td><img alt="file" src="../../images/eng/common/icon_file.gif"/></td>
<td>1821</td>
</tr>
<tr>
<td>201</td>
<td class="left"><a href="d03895e98485f90135248f1fb71507df">National Safe Hospital_Entire List</a></td>
<td>2015-06-19</td>
<td><img alt="file" src="../../images/eng/common/icon_file.gif"/></td>
<td>2423</td>
</tr>
<tr>
<td>200</td>
<td class="left"><a href="dfe801aa78ada3707e6a4e675ca2bb6c">Press Release Summary (June 19)</a></td>
<td>2015-06-19</td>
<td><img alt="file" src="../../images/eng/common/icon_file.gif"/></td>
<td>2220</td>
</tr>
<tr>
<td>199</td>
<td class="left"><a href="018002895987aec98261a097ed4dde79">Hospitals with Known MERS Exposure</a></td>
<td>2015-06-19</td>
<td><img alt="file" src="../../images/eng/common/icon_file.gif"/></td>
<td>1640</td>
</tr>
<tr>
<td>198</td>
<td class="left"><a href="09f72e386c73fd723c20199fe6d07228">MERS Statistics (June 19)</a></td>
<td>2015-06-19</td>
<td><img alt="file" src="../../images/eng/common/icon_file.gif"/></td>
<td>2356</td>
</tr>
<tr>
<td>197</td>
<td class="left"><a href="ea1a8f9ca266ce7697a42aa208fa08bd">Press Release Summary (June 18)</a></td>
<td>2015-06-18</td>
<td><img alt="file" src="../../images/eng/common/icon_file.gif"/></td>
<td>1752</td>
</tr>
<tr>
<td>196</td>
<td class="left"><a href="a263cea461913e8b28b0a3d5d75c0b54">MERS Statistics (June 18)</a></td>
<td>2015-06-18</td>
<td><img alt="file" src="../../images/eng/common/icon_file.gif"/></td>
<td>1659</td>
</tr>
</tbody>
</table>
<!-- /table:list -->
<!-- paging -->
<!-- paging -->
<div id="paging">
<a class="btn" href="ebfb6bc3f850eb20122e1021c6e4c0d1"><img alt="first page" src="../../images/eng/common/btn_firstpage.gif"/></a>
<a class="btn" href="ffdc4366d327476f2a2bdd61bea75d3f"><img alt="pre page" src="../../images/eng/common/btn_prepage.gif"/></a>
<a href="b5ac7ead72941feddd2152cd97408423" title="11page">11</a> 

				<a href="43305223367df6986d635c77763975b3" title="12page">12</a> 

				<a href="2711dbddb6de0a13625580768c3557fa" title="13page">13</a> 

				<a href="291c7b2c06ad0f481977e50fbd85795e" title="14page">14</a> 

				<span title="present">15</span> 

				<a href="3d5e6982b8cfbd3ae4834a4e77e21144" title="16page">16</a> 

				<a href="32fde42f13158f6b4f430ac227830ad3" title="17page">17</a> 

				<a href="e9a17658ff68b1011b3bf38b014eea17" title="18page">18</a> 

				<a href="3fbff7a5c45a170ce3270ba839fff4fb" title="19page">19</a> 

				<a href="095823f82b64fc9c0ab92d552e48e0b3" title="20page">20</a> 

				<a class="btn" href="6c8765ade6af448afd7277d09046c33a"><img alt="next page" src="../../images/eng/common/btn_nextpage.gif"/></a>
<a class="btn" href="2d7e34ab1d5e2a71b1530de73fd24299"><img alt="last page" src="../../images/eng/common/btn_lastpage.gif"/></a>
</div>
<!-- /paging -->
<!-- /paging -->
</form>
<!-- DB ¿¡¼­ contents µ¥ÀÌÅÍ¸¦ °¡Á®¿Í¼­ »Ñ·ÁÁØ´Ù. -->
</div>
</div>
<!-- /contents -->
</div>
</div>
<!-- footer -->
<!-- footer -->
<div id="footer">
<div class="foot">
<p class="flogo"><img alt="ministry of health and welfare" src="../../images/eng/common/flogo.gif"/></p>
<div class="finfo">
<address><img alt="13, Doum 4-ro, Sejong, (30113) Korea ¤ÓCALL CENTER 82-129" src="../../images/eng/common/foot_address.gif"/></address>
<p class="copyright"><img alt="Copyright(C) By MOHW. All rights reserved." src="../../images/eng/common/foot_copyright.gif"/></p>
</div>
<!-- ÀÏÀÏ¹æ¹®ÀÚ¼ö Ãß°¡ -->
<p class="visits">Daily visits : <strong>198</strong></p>
<!--// ÀÏÀÏ¹æ¹®ÀÚ¼ö Ãß°¡ -->
</div>
</div>
<!-- //footer -->
</div>
<div id="returntotop"><a href="#skip-navi">go to the top</a></div>
<script type="text/javascript">
//<![CDATA[
function jsOpenSite(formEl) {	
	var errorMessage = null;
	var objFocus = null;
	if (formEl.sitelink.value.length == 0) {
		errorMessage = "please! select a site to move!";
		objFocus = formEl.sitelink;
	} 
	if(errorMessage != null) {
		alert(errorMessage);
		objFocus.focus();
		return false;
	}
	return true;
}
//]]>	
</script>
<script type="text/javascript">
  (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
  (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
  m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
  })(window,document,'script','https://www.google-analytics.com/analytics.js','ga');

  ga('create', 'UA-101800795-1', 'auto');
  ga('send', 'pageview');

</script>
<!-- /footer -->
</div>
</body>
</html>